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Introduction: Treatments of retinoic acid, a metabolite of vitamin A (VA) are shown to 
induce hyperlipidemia in humans and animals, which may influence adiposity.  To 
understand the role of VA in weight management, two studies, one in animals examining 
effects of VA combined with high-fat diet (HFD) on body mass (BM) gain and the second 
in humans comparing dietary VA between participants who were overweight/obese and 
who had and had not lost 10% of body weight by consuming a hypocaloric, low-fat diet, 
were conducted.  
Methods: Male Sprague Dawley rats were fed a HFD containing sufficient VA (HF-VAS) 
or a HFD deficient in VA (HF-VAD) for eight weeks. BM, liver mass, white adipose mass, 
brown adipose mass and plasma glucose were measured.  The groups were compared 
with student's t-test.  For the second experiment, participants (51.9 ± 8.8 yrs, 35.0 + 4.5 
kg/m2, 94.7% white, 59.6% female, 100% non-hispanic) in a lifestyle intervention were 
categorized as successful weight losers (loss of > 10% body weight) or unsuccessful 
weight losers  (loss of < 10% body weight) after 6 months of treatment on a hypocaloric, 
low-fat diet. Dietary intake, assessed by three, 24-hour dietary recalls was collected at 6 
months.  Dietary VA was compared between the groups using analysis of covariance. 
Results: In the animal study, significant differences were detected in end day BM, liver 
mass and white adipose mass between the HF-VAS and HFD-VAD groups.  No 
significant difference was detected in dietary VA consumed between participants who had 




Conclusion: Results from the animal experiment indicate that VA plays a role in adiposity 
in subjects consuming an obesogenic diet. No difference was detected in VA intake 
between subjects who successfully lost 10% weight and those who have not.  This 
indicates dietary VA is not related to successful weight loss on a hypocaloric, low-fat diet.   
Additional studies are needed to understand the role VA plays in obesity development.  
Also, further investigation on how VA intake while consuming a hypocaloric low fat diet 
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1.1 Background  
Obesity, defined as excessive body fat content indicated by a BMI ≥ 30 kg/m2, 
continues to be a nationwide problem with one third of Americans considered to be 
obese1.  This epidemic predicts the development of various metabolic diseases2, 
resulting in higher mortality rates and higher costs in health care3.  Aside from this, obesity 
has been linked to decreased productivity in the workplace, which can indirectly increase 
healthcare costs3.  The increases in mortality rates and costs of health care have become 
an urgent problem, which finding solutions must become priority.   
Obesity is thought to be caused by positive energy balance, meaning that energy 
intake is greater than energy output4.  Both genetic and environmental factors contribute 
to the development of obesity and its associated chronic metabolic diseases. Several 
genes, such as leptin and its receptor, responsible for monogenic obesity have been 
identified5. On the other hand, over nutrition seems to be an obvious cause of obesity 
development. However, the role of each micronutrient has not been revealed. Previous 
research indicates that VA may also play a role in the development of obesity6.  This 
thesis includes two parts. The first one aims to investigate the contributions of VA intake 
on obesity development in rats fed a high-fat diet (HFD). The second portion studied the 
effects of VA intake on body weight alterations in participants during a hypocaloric, low-
fat diet.  The project seeks to answer the following questions:  Does the presence of VA 
in the diet have an effect on weight gain while subjects are consuming a high-fat 
obesogenic diet?  Is there a significant difference in the amount of dietary VA consumed 
by partcipants who successfully lost weight while consuming a hypocaloric, low-fat diet 
compared to those who did not in a clinical weight loss trial?  The two experiments use 
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different models to answer the questions.  The first experiment uses an animal model 
looking at weight gain on a high-fat diet, while the second experiment uses a human 





































2.1 Vitamin A (VA) and its homeostasis 
2.1.1 The discovery of VA and provitamin A 
VA, all-trans retinol ((2E, 4E, 6E, 8E)- 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-
enyl) nona-2,4,6,8-tetraen-1-ol)),  is a lipid soluble vitamin which exists in multiple 
isomeric forms7.  All of these forms contain a 20 carbon structure with a methyl substituted 
cyclohexenyl ring and a tetraene side chain differing in the molecules attached to this side 
chain7.  It was first identified in 1910s and later elucidated in 1930s as a lipid derived 
factor essential for the growth of animals8,9.   
VA activity was observed when rats fed a synthetic diet with lard or olive oil 
extracted with ether as the only fat source would lose weight and then die.  In contrast, 
rats given certain lipid derived factors from foods such as eggs and butter survived and 
began to grow again10.  Later on, its molecular identity as retinol was determined. VA 
activity can be derived from molecules that can be converted into retinol11.  In the diet, 
these molecules are retinol esters (animal sources) and provitamin A carotenoids (plant 
sources)12. The majority of VA physiological activities are mediated by RA13.  Retinol (an 
alcohol) is first reversibly oxidized into retinal (an aldehyde), and then irreversibly oxidized 
into RA. It has been recognized for its role as essential micronutrient for the general health 
of the individual.  In the body, VA is essential for vision, growth, skin development and 
cell differentiation14. 
2.1.2 The discovery of carotenoids 
Carotenoids were discovered as a result of the search for a medicinal agent, an 
anthelminthic to rid the body of parasitic worms, especially from the intestine15. Credit 
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for this discovery goes to Heinrich Wilhelm Ferdinand Wackenroder15.  He published the 
results of his examination of carrots, with one of the purposes of that research being the 
search for the presence in the juice of the carrots of an effective anthelminthic15. This 
prompted Wackenroder to undertake chemical analysis of the juice in the attempt to 
identify the substance that was medically active15. The results of this work were 
published in 183115. 
In humans, three carotenoids (beta-carotene, alpha-carotene, and beta-
cryptoxanthin) have VA activity, and these and other carotenoids can also act as 
antioxidants10.  In the body, provitamin A carotenoids are cleaved to form retinal, which 
is then reduced to retinol12. 
2.1.3 VA metabolism and its active metabolic intermediates 
Retinol, the least potent form of molecules with VA activities, contains a hydroxyl 
group at carbon-15.  Retinol can act as a precursor for the more active forms of molecules 
with VA activities.  When retinol is oxidized to retinal the molecule contains an aldehyde 
group, which is  further oxidized to RA containing a carboxylic acid group7.  VA activity 
can be derived from molecules that can be converted into retinol11. The majority of VA 
activities are mediated by RA13.   
Enzymes responsible for the reversible oxidation/reduction reaction of retinol to 
retinal are termed dehydrogenases and exhibit properties as an alcohol dehydrogenase 
or a short- chain dehydrogenase reductase16. Enzymes facilitating the irreversible 
oxidation of retinal to RA are classified in the aldehyde dehydrogenase family16.  
Cytochrome P450 hydroxylase 26A (CYP26A) mediates modification of RA molecules to 
facilitate RA disposal. It is the primary CYP26 enzyme expressed in the liver, contributing 
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the largest amount of activity in the clearance of RA from humans17. This gene irreversibly 
oxidizes RA into more polar metabolites for excretion17. 
2.1.4 The conversion of carotenoids to VA 
Of all known carotenoids, β-carotene is believed to be the most important in human 
nutrition18.  The key step in the VA biosynthetic pathway is the oxidative cleavage of β-
carotene into two retinal molecules by the enzyme β,β-carotene-15,15′-
monooxygenase18.  Subsequent oxidation yields retinoic acid which can then act as ligand 
for nuclear transcription factors.  Beta-carotene can also undergo eccentric cleavage 
which can occur enzymatically or non-enzymatically19. This produces beta-apocarotenals 
and beta-apocarotenones, whose functions in mammals are unknown19. 
2.1.5 Digestion, absorption and storage of VA and carotenoids 
Dietary  VA comes from retinyl esters (animal sources) and provitamin A 
carotenoids (plant sources)20.  Carotenoids consist of 40 carbons, conjugated double 
bonds, and may contain 1-2 cyclic structures at the end of their chain7.  Pancreatic 
lipases hydrolyze retinyl esters into retinol and free fatty acids which then are absorbed 
into enterocytes.  Retinol is then re-esterified into retinyl esters to be packaged in 
chylomicrons for delivery to other parts of the body through lymph circulation first and 
then blood circulation20.  Provitamin A carotenoids are enzymatically cleaved to produce 
retinal which is then reduced into retinol12,21.  This retinol produced is then converted to 
retinyl ester so that it can be incorporated into chylomicrons22.  Dietary fat is essential 
for optimal absorption of VA because it acts as a facilitator for incorporation into 
chylomicrons23.  Foods rich in VA include liver, milk, eggs, and those rich in provitamin 
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A include carrots, sweet potato and dark leafy greens10.  The RDA for VA has been 
established for the different life stages to prevent deficiency and toxicity24.  See Table1 
below for RDA of VA.  
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 Physiological VA status is regulated through a network of enzymes and proteins 
which facilitate the transport, productions and catabolism of retinoids25. In this network, 
retinol is reversibly converted into retinal, and retinal is irreversibly converted into RA26.  
RA has been involved in the regulation of the expression levels of the enzymes in this 
system 13. However, it is important to recognize that some of the physiological functions 
of retinal (such as vision) cannot be replaced through RA treatments27.   
2.1.6 Mechanisms of VA and its metabolites functions 
2.1.6.1 The vision cycle 
Retinol metabolite, 11-cis-retinal, plays a critical role in vision.  In the eyes, 11-
cis-retinal is bound to opsin to form rhodopsin in rods.  When light enters the eyes, 11-
cis-retinal isomerizes to all-trans-retinal and dissociates from opsin.  This results in a 
nervous signal along the optic nerve to the brain.  A series of enzymatic reactions 
9 
 
converts all-trans-retinal back to 11-cis-retinal, which can then rebind to opsin to form 
rhodopsin to complete the vision cycle10 
2.1.6.2 Mechanism of Retinoic Acid (RA)-mediated transcription 
 RA is found in multiple forms, with all-trans RA and 9-cis RA being significant in 
the body.  RA regulates gene expression mainly through activating two nuclear receptor 
families, RA receptors (RARα, β and γ) and retinoid X receptors (RXRα, β and γ)12,26.  
RARs and RXRs are considered part of the nuclear receptor family, which are ligand-
activated transcriptional activators critical for physiological processes28,29.  RARs are 
activated by all-trans RA while RXRs are activated by 9-cis RA26.  Activation occurs 
when RAR/RXR hetero-dimers or RXR/RXR homo-dimers bind to the RA responsive 
elements at the promoters of their downstream targeted genes30,31.  It has been 
suggested that RXR can act as a universal dimerization partner for other families of 
nuclear receptors such as peroxisome proliferator activated receptors (PPARs), liver X 
receptor (LXR), thyroid hormone receptor (TR), and vitamin D receptor (VDR), 
indicating a complex transcriptional network which allows RA, to exert its biological 
activity.32. 
 Chicken ovalbumin transcription factor II (COUPTF-II) nuclear receptors have 
DNA-binding abilities, meaning it can activate or inhibit gene expressing  depending on 
the presence of ligands, corepressors or coactivators33.  Deletion of COUPTF-II can 
alter processes such as angiogenesis and cardiovascular development, and therefore 
can be lethal33.  It has been reported that COUPTF-II acts constitutively but its activity 
can be modulated by the presence of RA34.  RA has been reported to release COUPTF-
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II from the auto-repressed conformation, possibly affecting some of the metabolic 
activities regulated by COUPTF-II34. 
 Hepatocyte nuclear factor 4 alpha (HNF4α) is a transcription factor responsible for 
several liver specific functions such as gluconeogenesis and lipid and bile synthesis35.  
It has been shown to direct 11% of genes actively transcribed in pancreatic islets36.  
Compared to the liver, it is expressed in lower amounts in other tissues such as 
intestine and kidneys37.  The importance of the role it plays is indicated by the 
development of hepatic steatosis in HNF4α deficient mouse livers35.  In humans, 
mutations in the HNF4α genes leads to maturity onset of type I diabetes, characterized 
by pancreatic β-cell dysfunction evidenced by loss of insulin secretion in response to 
glucose38.  In hepatocyte, HNF4α maintains differentiation state, phenotype and also 
directs energy metabolism38.   
It has been observed that RA produced in intestines was found in the portal 
system of the liver39, which indicates that plasma RA levels may play a role in signaling 
the body’s retinoid status13.  It has been demonstrated that retinoids regulate the 
expression of genes involved in hepatic glucose and lipid metabolism40,41. 
2.2 Hepatic metabolism of VA 
The liver plays an essential role in energy metabolism. This is in part attributed to 
the regulation of expression levels of hepatic genes involved in glucose and lipid 
metabolism in response to hormonal and nutritional stimuli42.  Obesity and other metabolic 
diseases such as diabetes have been linked to abnormal glucose and lipid metabolism in 
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the liver43.  It is clear that metabolic abnormalities significantly impact hepatic functions 
and, thereby, contribute to morbidity. 
2.2.1 Role of liver in the regulation of metabolic homeostasis  
The liver is the most important site for retinoid storage in the body, accounting for 
uptake of 66-75% of all dietary retinoid absorbed in the intestines44.  It accounts for 70-
80% of all retinol binding protein (RBP) in circulation, making it the major site for RBP 
synthesis and secretion22.  RBP maintains circulating levels of retinol to assure 
continuous delivery to target tissues under conditions of retinoid sufficiency45.  The three 
RARs (α, β, γ) and three RXRs (α, β, and γ) are all expressed in the liver, making it an 
important target organ for retinoid actions46. 
2.2.2 Role of the liver in VA homeostasis and its metabolism 
The majority of dietary retinol absorbed by enterocytes is secreted into the 
lymphatic system in the form of retinyl esters in chylomicrons, which contain dietary 
lipids, mostly triglyceride (TG) and cholesterol22.  In circulation, 66-75% of chylomicron 
retinyl ester is removed by the liver while the remaining is removed by extrahepatic 
tissue such as adipose tissue, skeletal muscle, heart, spleen and kidney22.  Most retinyl 
ester present in chylomicrons remains as the particles become chylomicron remnants in 
a process involving the lipolysis of TG and recruitment of apolipoprotein E (apo E) to the 
particles22.  It is thought that chylomicron remnants are internalized solely by 
hepatocytes47. 
After chylomicron remnant retinyl esters have been up taken by hepatocytes, the 
retinyl esters are hydrolyzed by retinyl ester hydrolases48.  In a retinoid sufficient state, 
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chylomicron remnant retinol is then transferred to hepatic stellate cells for storage49,50.  
In contrast, when dietary retinoids are insufficient more of the recently ingested retinol is 
secreted into circulation bound to RBP instead of being transported into storage. 
Circulating retinol bound to RBP enters and leaves the liver multiple times before 
its elimination from the body.  This process is called retinol recycling51.  Studies in 
humans show that 14.3 mg/day of retinol passes through plasma compared with a 
disposal rate of 1.14 mg/day, which indicates that a large portion of retinol take up in 
organs and circulating tissues is recycled back into plasma and that only a minor portion 
is converted to active metabolites or degraded52.  It is thought that this process of retinol 
recycling provides the liver an ideal means to sample and adjust the concentration of 
retinol available in plasma for peripheral tissue53.  Total body retinol pool size can be 
estimated with deuterated retinol dilution technique and calculation of the change in 
total body retinol pool size can be achieved with the paired deuterated retinol dilution 
technique54,55. 
Hepatocytes play an essential role in hepatic retinoid metabolism and storage, 
accounting for some retinoid storage and facilitating mobilization of retinol from the 
liver22.  These cells also contribute to retinoid activation to RA, to RA catabolism and to 
the excretion of retinoid catabolic products22.  They have relatively high concentrations 
of retinol, retinyl ester, RBP, retinyl ester hydrolases, and enzymes that convert retinol 
to RA22. 
Mobilization of retinoids from the liver to target tissues in circulation is regulated 
in a process involving RBP56.  RBP has a molecular weight of 21 kDa and has a single 
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binding site for one molecule of all-trans retinol22.  This protein is synthesized in 
hepatocytes, but its expression has also been detected in other tissues, such as kidney 
and adipose tissue22.  When retinol binds to RBP, the retinol-RBP complex enters the 
blood stream for transport to target tissues and its concentration is maintained at 2-3 
μM.  This complex circulates in the blood as a 1:1 molar complex with thyroxine 
hormone carrier transthyretin, making the complex less susceptible to filtration by the 
kidney57,58 
2.2.3 Role of VA in the metabolism of glucose in the liver 
Elevation of hepatic VA content was observed in diabetic patients as early as 
193759.  Later, it was observed that rats fed a VA-deficient (VAD) diet had depleted 
hepatic glycogen content60.  This study concluded that the depletion of hepatic glycogen 
was caused by the reduction of glycogenesis from trioses, rather than directly from 
glucose60.  The depletion in VAD rats was not due to reduced energy intake, as pair fed 
rats with equal energy intake had higher hepatic glycogen content60.  When rats were 
fed a diet with excess VA for 2 days, a dramatic increase in fasting hepatic glycogen 
content was observed61. 
It has been observed that insulin resistant humans and animals have elevated 
plasma RBP 462.  When mouse plasma RBP4 level was manipulated, the result was 
altered insulin sensitivity and expression levels of hepatic gluconeogenic genes63.  A 
reduction of plasma retinol and RBP levels has been observed in patients with type I 
diabetes and also in streptozotocin-induced diabetic rats64,65.  Insulin sensitivity was 
improved in insulin resistant ob/ob mice with administration of retinal66.  
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Glucose is differentially metabolized in cells depending upon hormone and 
nutrition statuses67.  For it to be utilized, it must undergo phosphorylation to become 
glucose 6-phosphate (G6P) through the action of hexokinases in the first step of 
glycolysis.  In mammals, hexokinase is referred to as glucokinase (GK)68,69.  Mutations 
altering the GK enzymatic activity are associated with maturity onset diabetes of the 
young70.  Regulation of hepatic GK activity is accomplished by its binding to GK 
regulatory protein, phosphorylation by protein kinase A, and interaction with cytosolic 
GK-associated phosphatase71-73.  Long term regulation of GK activity is achieved 
through transcription of GK gene (Gck)74.  Gck is differentially regulated by an upstream 
promoter in pancreatic β-cells and a downstream promoter in hepatocytes75.  In the 
liver, the cycle of fasting and re-feeding alters Gck expression. However the same cycle 
does not alter Gck expression in pancreatic β-cells74.  It has been observed that in rat 
liver, Gck mRNA is induced by insulin and suppressed by glucagon76-78.   
In rat hepatocytes, all-trans RA has been shown to induce Gck expression 
without any additive effects on insulin mediated induction79,80.  On the other hand, our 
research group has reported that retinoids synergize with insulin to induce Gck 
expression in rat hepatocytes40.  In the liver of VAD rats, Gck activity and mRNA levels 
were lower compared to VAS controls.  Also, treatment with RA induced Gck mRNA in 
rat hepatocytes40. 
Under conditions where dietary glucose is not available, the liver will produce 
glucose through gluconeogenesis.  Phosphoenolpyruvate carboxykinase (PEPCK-C), 
the first rate-limiting enzyme of gluconeogenesis, converts oxaloacetate into 
phosphoenolpyruvate in the presence of GTP81.  PEPCK-C expression and activity has 
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been detected in the liver, kidney and adipose tissues, where PEPCK-C may control 
gluconeogenesis, glyceroneogenesis and cataplerosis81-84.  PEPCK-C is regulated by 
the transcription of its gene Pck1 in different physiological conditions81-83. The hepatic 
expression of Pck1 is induced by glucagon and suppressed by insulin85, meaning the 
liver can produce glucose under fasting conditions.  RA has been reported to stimulate 
Pck1 expression, also two RA response elements (RARE) have been identified at Pck1 
promoter in hepatoma cells86-88.  Lipophilic extract from rat liver was found to induce 
Pck1 expression and attenuate insulin-mediated suppression of its transcription89.  
These lipophilic molecules were later identified as retinoids due their effects of insulin-
induced Gck expression40.  Of the two previously identified RARE in Pck1 promoter, the 
proximal one was responsible for mediating the retinoid effect in hepatocytes86,87,90,91.   
2.2.4 Role of VA in the lipid metabolism 
The liver and adipose tissues, in response to dietary intake and stored energy, 
regulate TG and fatty acid (FA) homeostasis in the body92,93.  FAs are stored in adipose 
tissue as TGs in the postprandial stage94.  TG in chylomicrons and very low density 
lipoprotein (VLDL) is converted to free fatty acids (FFA), monoglycerides and 
diglycerides through hydrolysis by lipoprotein lipase (LPL) for entry and storage in 
adipose tissues.  Under fasting or starvation condition, FFAs are released from adipose 
tissue though lipolysis by lipases in adipocytes95.  These FFAs can then be used by 
heart, liver and skeletal muscle for energy.  In the liver, FFAs can be used for 
ketogenesis and glycerol for gluconeogenesis.  Other organs, like the brain, can then 
utilize ketone bodies and glucose for energy. 
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Instances of metabolic abnormalities are often associated with changes in 
hepatic lipid metabolism.  For instance, patients or animals with obesity and type 2 
diabetes were reported to have excessive hepatic lipogenesis43.  Insulin stimulates 
lipogenesis and inhibits lipolysis to regulate FA and TG homeostasis96.  Patients and 
animals with obesity and type 2 diabetes experiencing hyperinsulinemia were 
determined to have excessive hepatic production of FAs and TGs.  This happens 
because the liver can stimulate the expression of lipogenic genes, a process mediated 
by sterol regulatory element binding protein 1c (SREBP-1c), which is an insulin-induced 
transcription factor97,98.  In the liver of mice, activation of liver X receptor (LXR) and RXR 
induced the expression of the SREBP-1c gene (Srebp-1c)99.  In Srebp-1c promoter, the 
insulin responsive elements have been identified as two liver X receptor elements 
(LXRE) and one sterol regulatory element (SRE)100.  Retinoids induced SREBP-1c 
expression and maturation, resulting in activation of the promoter activity of fatty acid 
synthase gene (Fas)101,102.  In rat hepatocytes, retinoids synergized with insulin to 
induce expression of Srebp-1c mRNA in a dosage and time dependent manner41.  The 
two LXREs responsible for the insulin induced Srebp-1c expression in rat hepatocytes 
were determined to be RAREs in its promoter41,100. 
Patients with acne treated with isotretinoin (13-cis RA) developed 
hypertriglyceridemia103.  Healthy subjects given isotretinoin had elevated plasma apo C-
III level.  In adult hepatocytes, apo C-III was induced RXR specific agonist104.  Patients 
with acute promyelocytic leukemia were observed to have gained weight and elevated 
levels of plasma TG and cholesterol after treatment of all-trans RA105,106.  Rats 
consuming a VAD diet for 3 months after weaning were reported having lower plasma 
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TG and cholesterol, hepatic phospholipid contents, and hepatic synthesis of FA and 
phosphatidylcholine compared to controls fed a VAS diet107.  This may be due to the 
combination of VA deficiency and hypoinsulinemia, because insulin secretion is 
impaired in rats fed a VAD diet108.  Rats fed with all-trans RA and 13-cis RA and with 9-
cis RA and RAR specific agonist induced hypertriglyceridemia109,110.   This is attributed 
to the elevated production of VLDL in the liver and reduced uptake of TG in adipose 
tissue and skeletal muscle.  In vitro experiments show that rat hepatocytes treated with 
RA increased the incorporation of lipid precursors into FA and TG.  Reduced TG uptake 
was associated with reductions of LPL activities in adipose tissue and skeletal 
muscle109.  Elevated plasma TG was reported for Sprague-Dawley and Zucker diabetic 
fatty rats treated with a RXR specific agonist111.   This was attributed to a decrease in 
LPL activities in adipose tissue and skeletal muscle111.  The reduction was likely 
mediated by a RXR-induced protein responsible for posttranslational processing of PLP 
since there were no effects of RXR activation on the mRNA level of LPL111.  It is 
important to note that the role of hepatic lipogenesis in the increase of plasma TG was 
not clearly defined in these studies.  In obese and diabetic mice, it has been reported 
that RXR sensitized insulin and reduced TG levels112.  All-trans RA has been reported 
to repress obesity and insulin resistance through activation of PPAR β/δ and RAR113.  
Hepatic lipid metabolism was altered in mice with liver specific knockout of RXRα114.  Of 
note, RXRα knockout mice have elevated expression of RARβ and RARγ, which implies 
the changes of RA signaling as RARβ can be up-regulated with treatment of RA115. 
 These observations imply the roles of VA in lipid metabolism, probably through 
multiple mechanisms12.  Treatment of RA may have (1) increased lipogenesis in the 
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liver, (2) reduced PLP activity in skeletal muscle and adipose tissue, and/or activated 
signal transduction pathways and transcription of RAR/RXR downstream targeted 
genes116.  The two RAREs/LXREs on Srebp-1c are mediating insulin response and 
sensing nutrition VA status, meaning the retinoid and insulin signaling pathways can 
converge on the same sites in Srebp-1c promoter and synergize to induce its 
expression, resulting in the expression of its downstream lipogenic genes12.  Because 
SREBP-1c is the dominating regulator for hepatic FA biosynthesis, it has been 
concluded that one of the ways that retinoids regulate lipid homeostasis is through 
regulation hepatic expression of Srebp-1c 12,97.  Looking at the effects of RA on insulin-
mediated expression of Srebp-1c and Pck1 in rat hepatocytes, it has been suggested 
that RA may be one of the possible factors leading to hepatic insulin resistance12,41,91. 
2.2.5 Role of VA intake in obesity development 
Previous research indicates that VA plays a key role in the development of obesity. 
Patients with promyelocytic leukemia treated with all-trans RA had observed increases in 
BM and plasma cholesterol105.  Excess of isotretinoin (13-cis RA) given to patients for the 
treatment of acne vulgaris has been shown to elevate blood TG and liver enzymes without 
any change in dietary intake117,118.  It has been demonstrated that Zucker fatty rats fed a 
VAD diet gained significantly less weight than their VA sufficient counterparts6.  It has 
been observed that patients with metabolic syndrome had significantly lower levels of 
plasma VA than their healthy counterparts119.  Interestingly, research has demonstrated 
the use of VA in the treatment of obesity.  Obese mice treated with all-trans RA 
experienced weight loss and improved insulin responsiveness as a result of the all-trans 
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RA inducing the expression of PPAR β/δ and RAR target genes involved in regulating 
lipid homeostasis113.    
The impact of VA on the mechanisms of obesity development is not well 
understood.  A greater understanding of the role of VA in energy metabolism and obesity 
development may lead to more effective treatments for obesity and metabolic diseases. 
2.3 Methods to assessing VA 
2.3.1 Measuring VA in plasma 
 Methods have been established to quantify VA in plasma.  Plasma samples first 
undergo an extraction process to remove the fat soluble vitamins and carotenoids.  This 
extraction provides an extract suitable for reversed-phase liquid chromatography 
analysis with absorbance detection120.  Below is Table 2 for normal retinol plasma 
levels. 
 
Table 2 Reference Intervals for normal retinol plasma levels in humans based on age 
Life Stage Reference Interval 
0-1 month 0.18-0.50 mg/L 
2 months-12 years 0.20-0.50 mg/L 
13-17 years 0.26-0.70 mg/L 







2.3.2. Measuring VA in the tissues 
 For establishing tissue concentration of VA, there is far less data than for plasma 
concentration10.  Research indicates greater concentrations in tissue than plasma in 
rats10.  For instance, it has been reported that normal rats have tissue concentrations 
ranging 40-580 pmol/g (kidney, liver, lung and pancreas) compared to a plasma 
concentration of 8-16 pmol/ L10. 
2.4 Role of western diet in the development of metabolic diseases 
2.4.1 High-Fat Diet (HFD) 
2.4.1.1 The definition of HFD and current status in population 
With one third of Americans being considered obese, obesity has reached 
epidemic level in the United States1.  This is a concern of public health as obesity leads 
to the development of various metabolic diseases2, which result in higher mortality rates 
and higher costs in health care.      
One of the dietary styles contributing to the obesity epidemic is the Western Diet 
(High-fat content), which is characterized by a high intake of red and processed meats, 
eggs,  refined grains and sugars, and energy derived from fat, mainly saturated fatty 
acids, which can be as high as 35% of energy intake121,122.  The Dietary Guidelines 
published by the USDA recommends that dietary fat provide 20-35% of energy, 
emphasizing consumption of n-3 polyunsaturated fatty acids (PUFA) while limiting the 
intake of saturated and trans fatty acids123.  It has been reported that the fat intake of an 
average adult is 33% of energy intake124.  However, it is important to note that adults 
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may consume more total kcal than recommended so fat intake would still be higher than 
recommended.   
2.4.1.2 Studies using HFD 
The consequences of consuming a HFD have been documented in human and 
animal subjects.  The HFD pattern has been positively related to BMI and has been 
linked to increased risk for type 2 diabetes, coronary heart disease and colon cancer122.  
The intake of a HFD not only increases risk for these diseases, but also reduces 
functions of the immune system121.   Additionally, high fat diet consumption may induce 
inflammatory pathways in individuals121.     
The detrimental effects of HFD consumption have been studied in animals 
extensively. For example, mice fed a HFD (45% energy from fat) for 12 weeks 
developed obesity, hyperinsulinemia, hyperglycemia, and hyperleptinemia125.  High fat 
feeding alters mechanisms for digestion and absorption.  Mice fed a HFD demonstrated 
significant differences in transcript levels of pancreatic enzymes compared to 
controls125. Sprague Dawley rats placed on a HFD for 10 weeks demonstrated greater 
oxidative stress (measured by serum levels of urinary-8-epi-prostaglndin-F2α and 
glutathione peroxidase) than controls fed a normal chow diet126.   
Preventing the intake or reducing the absorption of dietary fat has been shown to 
be beneficial to control the development of metabolic diseases. Reducing fat absorption 
may alter the outcomes of HFD feeding. Patients with obesity receiving120 mg three 
times/day of Orlistat(a drug that acts as a lipase inhibitor, preventing the digestion and 
then, absorption of dietary fat) for one year had significant reduction of body weight in 
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association with decrease in levels of vitamin E (VE) and β-carotene, but not VA and 
vitamin  D (VD), compared with those receiving placebo, indicating the essential role of 
fat absorption in the maintenance fat-soluble vitamin homeostasis127.  On the other 
hand, a 12-week treatment of Orlistat (120 mg three times daily) significantly reduced 
the plasma levels of VA and VE in addition to the reductions of body weight and fat 
mass in patients with obesity128. 
2.4.2 Lipophilic vitamins in HFD conditions 
Based on their solubility in aqueous solution, vitamins are classified as either 
hydrophilic or lipophilic. Fat soluble or lipophilic vitamins are VA, VD, VE, and vitamin K 
(VK). They can be stored in the body. Historically, those lipophilic vitamins were 
identified due to the symptoms caused by their deficiencies in animal and human 
studies such as growth cessation in animals for VA and rickets for VD. 
Upon intake, lipophilic vitamins are digested, absorbed and embedded with 
dietary fat, and transported with chylomicrons through circulation. The major component 
of dietary fat, triacylglycerol in chylomicrons is delivered and stored into peripheral 
tissues due to the action of lipoprotein lipase in the body. It seems to be possible that 
the amount of dietary fats and their compositions may affect functions, availability and 
metabolism of lipophilic vitamins, which in turn may affect body health. Here, we try to 
summarize the current understanding and progress of human and animal research work 
regarding the effects of HFD intake on functions and availability of lipophilic vitamins. 
VD is incorporated into micelles and enters enterocytes through passive 
diffusion.  After absorption, VD is then packaged in chylomicrons in enterocytes and 
delivered throughout the body through lymph circulation.  VD synthesized in the skin is 
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transported through the body by VD-binding protein (DBP).  Once VD reaches the liver, 
either through chylomicron remnants removal or DBP, it is hydroxylated to 25-
Hydroxycholcalciferol (25-OH-D3)10,129.  
Within the small intestine, dietary VE is incorporated into micelles.  The pancreas 
secretes esterases that act on VE esters to yield free VE which then enters enterocytes 
through passive diffusion.  In enterocytes, VE is packaged in chylomicrons and 
delivered to the rest of the body through lymph circulation130. 
In intestine, dietary VK is incorporated into mixed micelles comprising dietary 
lipids, bile salts, and products of pancreatic lipases.131   Dietary VK is then absorbed 
into enterocytes through active transport.  VK is then incorporated into chylomicrons 
which will enter lymph circulation for delivery to other parts of the body131.  
Chylomicrons travel through circulation, are embedded into peripheral tissue and 
deposit cargo due to the action of lipoprotein lipase.  Chylomicron remnants are 
eventually taken by the liver where VK is incorporated into VLDL which re-enters 
circulation and can be up taken by osteoblasts.131  
Dietary intervention in humans can cause the change of plasma levels of 
lipophilic vitamins. In participants of a randomized, double-blind, placebo-controlled 
clinical trial, daily intake of 8.8 grams (g) of plant stanol esters for 10 weeks did not 
change serum levels of VA, VD and γ-tocopherol, but reduced the levels of total and 
LDL cholesterol, carotenes and α-tocopherol132. A 2.6 g/day dose also significantly 
reduce total cholesterol (LDL), total TG, and carotenes levels, but not VA and VE133.  In 
a moderately hypercholesterolemic population, sitostanol ester (3 g/day) for a year 
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significantly reduced the plasma levels of α-tocopherol and carotenes in association 
with the reduction of cholesterol, but not VA and VD levels134.  On the other hand, short 
term (2-7 days) intake of HFD in human, did not affect the plasma levels of cholesterol, 
TG, carotenes and VE135. 
The effects of VA in HFD feeding have been explored in animal models. 
Supplementation of additional VA in HFD caused further increase of plasma TG levels 
and expression levels of genes for adipocyte differentiation in rats already fed a HFD136.   
On the other hand, in male mice, a supplementation of VA (20IU /g of diet) in a HFD 
increased plasma levels of IL-18 and macrophage inflammatory protein-1 (MIP-1γ), 
which occurred in a RALDH1 (Aladh1 for gene)-dependent manner137.   
Adverse effects of excessive intake of VA on human and animals have been 
nicely summarized138.   Male Sprague-Dawley rats fed on a high-fat diet supplemented 
with large doses of chitosan have reduction of liver VA and VE, but not VK, levels, 
demonstrating the effects of dietary components on the fat soluble vitamin statuses in 
the body139.  It has been shown that dietary fat and fiber contents affect the VA storage 
in the liver and conversion of β-carotene into retinol in Mongolian Gerbils140. VA 
supplementation down-regulates leptin mRNA in adipose tissue in mice and RA 
stimulates UCP3 mRNA in muscle141. 
For VD to become activated, parathyroid hormone stimulates the kidneys to 
release the enzyme 1α-hydroxylase, which converts 25-OH-D3 to   1α,25-
Dihydroxycholecalciferol (1α,25-(OH)2D3)142.  DBP binds to 1α,25-(OH)2D3 so that it is 
carried to target tissues throughout the body where it can be a ligand for VD receptor 
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(VDR).  1α,25-(OH)2D3 enters cells and binds to VDR causing VDR to form a 
heterodimer with RXR which acts as a transcription factor to regulate gene 
expression10. 
There is an association of reduced serum 25-hydroxyvitamin D (25D) 
concentrations with the development of human obesity143. However, the effect of VD 
supplementation on body weight reduction seemed to be uncertain143. In children (6-10 
year-old), a slight lower value of serum 25D (drop from 26 ng/ml of nonobese to 23 
ng/ml of obese) was also associated with obesity144. A recent randomized controlled 
study using seven doses of VD (400–4800 IU/d) in both lean and obese female subjects 
showed that the rise of blood VD levels is inversely related to the body fat mass, and 
the normalization of blood VD levels is not associated with reduction of body weight in 
obese subjects145.  At this time there appears to be no published research investigating 
the effect of a HFD and VD intake and its plasma level in participants.   
Both male and female VD receptor knockout mice have a lean phenotype and 
demonstrate resistance to HFD-induced obesity regardless whether they are in the 
C57BL/6J or CD1 outbred background146-148. On the other hand, transgenic expression 
of human VDR driven by aP2 promoter in adipose tissue resulted in gains of BM and 
body fat mass in mice149. This phenotype is associated with the elevation of only plasma 
cholesterol level and changes of expression levels of genes for fuel metabolism in fat 
tissues and the skeletal muscle149. 
When SD rats were fed a diet containing low fat (LFD, 10% energy from fat) or 
HFD (45% energy from fat) with normal VD or depleted VD (VDD), rats in HFD-VDD 
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group had higher nonalcoholic fatty liver disease (NAFLD) activity Score (NAS) than 
rats in HFD-VD group. On the other hand, rats in LFD groups are protected to the 
development of NAFLD150. The elevation of NAS in rats of HFD-VDD group is 
associated with change of the expression of genes for hepatic inflammatory and 
oxidative stress, suggesting the protective role of VD to the development of NAFLD150. 
However, feeding HFD (40% energy from fat) in rats for 12 weeks per se did not change 
serum 1,25-dihydroxyvitamin D(3) level, whereas supplementation of lactose (10% of 
the diet weight) significantly reduce VD level and HFD-induced BM gain151. 
VE is a collective term for tocopherols and tocotrienols.  These molecules differ 
in their side chains; tocopherols have a phytol side chain while tocotrienols have an 
unsaturated side chain.  Only four tocopherols and four tocotrienols meet human VE 
requirements10, but in the human body α-tocopherol is the most effective152.  
  VE is of significant interest because it is a lipid soluble antioxidant.  It serves as 
a radical scavenger that protects polyunsaturated fatty acids in membranes and 
lipoproteins against lipid oxidation.  Alpha tocopherol scavenges a radical through 
donating a hydrogen with the resulting alpha tocopherol radical reacting with ascorbate 
to return to its reduced state.152  
It has been observed that overweight subjects (BMI ˃ 27) taking an antioxidant 
supplement (1g vitamin C/800 IU VE) with a high-fat low-carbohydrate diet (63.6 ± 1.6% 
calories as fat) for 8 days had a trend of lower C-reactive protein (30% reduction 
compared to baseline). One the other hand, subjects in the placebo group had a trend 
for higher levels of CRP (50% increase compared to baseline153.  
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 Several studies have been done in animals to determine the effects of VE in 
HFD condition. Feeding of VE did not affect the plasma lipid levels in lean or obese 
mice fed a HFD154. The HFD-induced activation of JNK in rat skeletal muscle was 
attenuated by including antioxidants including vitamin C and VE in Wistar rats155.  Male 
C57BL/6J mice fed a HFD (70% energy from fat) with elevated VE content had 
elevation of α-tocopherol in the liver and adipose tissues, which might be protective 
against lipid peroxidation156.  Supplementation of VE (α-tocopherol) or VD (D3) in HFD 
significantly reduced the plasma level of IL-6, but not IL-10, in HFD-fed male Swiss 
mice157.  Tocotrienol supplementation also reduced damages of feeding high-
carbohydrate and high-fat diet to the heart and liver in Wistar rats158.  A 6-week VE (α-
tocopherol) treatment at a dose of 100 mg/kg daily via oral gavages significantly 
reduced the memory impairment induced by High-fat and High-carbohydrate diet in rats, 
probably through reduction of oxidative stress in the hippocampus159.  Specific increase 
of VE content in mitochondria using a mitochondria-targeted VE derivative, MitoVit E 
(conjugated with triphenylphosphonium cations) has been shown to reduce hepatic 
oxidative stress and inhibit fat deposition in mice160.   
When mice were fed a HFD supplemented with α-tocopherol (VE, 0.9 g/kg of 
diet) and 1,25(OH)2 vitamin D3 (0.05 mg/Kg of diet) for 8 weeks, they had lower plasma 
levels of IL-6, indicating reduction of inflammatory response157. It was suggested that 
these two vitamins inhibit IL-6 production from adipocytes157.   HFD induced obese SD 
rats supplemented with 350mg/kg diet of DL-α-tocopherol acetate exhibited significantly 
less BM and fat weight126. 
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VK is essential in blood clotting and bone formation.  Quinone oxidoreductases 
reduce VK to vitamin K hydroquinone.  Vitamin K hydroquinone serves as a cofactor for 
vitamin K gamma-carboxylase, which catalyzes the carboxylation of certain glutamic 
acid residues, resulting in their activation in blood clotting and bone formation.  A 
reduced VK molecule is converted to vitamin K epoxide and then converted back to VK 
by vitamin K epoxide reductase161.  This reduction and reoxidation of VK coupled with 
glutamic acid carboxylation is referred to as the VK cycle10.  Because VK is recycled in 
the body, human deficiency of VK is rare161. 
Rats fed a HFD diet (45% more energy from fat) rich in corn oil had lower plasma 
VK level than those fed a low fat diet even more VK was present in the HFD, indicating 
the HFD feeding on the plasma level of fat-soluble vitamins162.  Additionally, the liver VK 
levels was reduced in rats fed a low-fat diet with fish oil, but not that fed a HFD (already 
lowered ) with fish oil163. 
2.5 Investigating weight loss in participants who are overweight and obese 
2.5.1 Current recommendations for obesity treatment 
 For the treatment of obesity in adults, comprehensive lifestyle interventions have 
been recommended164.  This consists of diet and physical activity goals, as well as 
behavioral therapy.  Dietary goals to achieve weight loss for adults who are overweight 
and obese should be individualized and include a 500 to 750 Calories/day deficit164.  
Physical activity goals aim to gradually increase the amount of physical activity to at 
least 30 minutes of moderate to vigorous intensity physical activity on as many days as 
possible.  Behavior therapy assists with behavior modification strategies, which are 
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implemented to change participants’ dietary intake and physical activity.  
Recommended behavior modification strategies to assist in changing diet and physical 
activity include stress management, self-monitoring, problem solving, stimulus control, 
cognitive restructuring, time management and social support164.  
2.6.2 Weight loss interventions in adults 
Typically weight loss interventions in adults include dietary changes, physical 
activity goals, and behavior modification.  A low-Calorie diet is currently recommended 
to aid in weight loss164.  The Dietary Guidelines, provided by the USDA, give standard 
recommendations for dietary changes.  For adults, it is recommended that dietary intake 
consists of 45-65% carbohydrates, 10-35% protein, and 20-35% fat123.  Many 
investigations on weight loss will limit participant dietary fat consumption to 30% or less 
of calories from fat165-167.  Current weight loss interventions in adults do not included 
prescriptions for VA intake so it is not well understood how VA intake may be related to 
weight loss. 
2.6 Conclusion 
 Obesity has reached epidemic levels with one third of this country’s population 
considered to be obese1.  This condition increases the risk of development of several 
metabolic diseases2, resulting in higher mortality rates and costs in health care3. This 
problem is multifactorial, with energy imbalance, genetics and environmental factors 
playing a role4-5.   
Previous research indicates that VA may also play a role in the development of 
obesity6.  It is clear that VA plays a role in glucose and lipid metabolism in both animals 
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and humans59-65, 92-116.  While VA intake has been shown to impact obesity 
development, research investigating VA and obesity development in adults is limited, 
with most of the research looking at the effects of excessive VA intake105, 117-118. 
One of the contributions to the obesity epidemic in this country is the Western 
dietary pattern, characterized by a HFD.  Consuming a HFD has been linked to 
increases in BM and risk of metabolic diseases121-125.  The current research on lipophilic 
vitamin in HFD has focused mostly on their protective roles in HFD feeding 
conditions129-153.     
Current recommendations for treatment of obesity in adults include dietary   
changes, physical activity goals and behavior therapy164.  A low-Calorie diet is currently 
recommended to aid in weight loss, with many weight loss interventions limiting fat 
intake to 30% or less of calories consumed164-167.  Currently, weight loss investigations 
in adults do not involve interventions for VA intake.  It is not clear how VA intake may be 
related to weight loss in adults. 
2.6.1 Specific aims 
This thesis includes two parts. The project seeks to answer the following questions:  
Does the presence of VA in the diet have an effect on weight gain while a high-fat, 
obesogenic diet is consumed?  Is the presence of VA in the diet related to successful 
weight loss when a hypocaloric, low-fat diet is consumed? This thesis project incorporated 
two different models to investigate the impact of VA in obesity.  The first is an animal 
model, where animals were fed a high fat diet with the goal of weight gain during dietary 
treatment.  The second model looked at adults, where participants’ fat and energy intake 
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were restricted with the goal of achieving weight loss.  The two experiments examined 
the following aims: 
1. Investigate the contributions of VA intake on obesity development in rats 
fed a high-fat diet (HFD).  
2. Investigate the effects of VA intake on body weight alterations in 
participants during a hypocaloric, low-fat dietary intervention. 
For this thesis project we hypothesized that VA intake will have an effect on 
obesity development when an obesogenic HFD is consumed.  We also hypothesized 
that achievement of 10% weight loss would be related to a lower dietary VA intake when 
weight loss was due to consumption of a hypocaloric, low-fat diet.  
It is important to note the use of different models for the experiments in this 
thesis.  Because one model investigated weight gain and the other investigated weight 
loss, two different mechanisms (weight loss and weight gain), as well as two different 








































 Obesity has become epidemic in this country with one third of Americans 
considered to be obese1.  This epidemic predicts the increased incidence of various 
metabolic diseases2, resulting in higher mortality rates and higher costs in health care3. 
The increases in mortality rates and costs of health care have become an urgent 
problem, so finding solutions must become priority. 
One of the dietary styles contributing to the obesity problem is the western diet 
(High-fat content), which is characterized by a high intake of red and processed meats, 
eggs,  refined grains and sugars, and energy derived from fat, mainly saturated fatty 
acids, which can be as high as 35% of energy intake121,122.  The Dietary Guidelines has 
recommended that dietary fat provide 20-35% of energy124.  It has been reported that 
the fat intake of an average adult is 33% of energy intake124, but it is important to 
recognize that adults may consume more total kcal than recommended so fat intake 
would still be higher than recommended.   
Lipophilic vitamins share the same routes of digestion and absorption as lipids.  
Previous research has established the impact of lipid digestion and absorption on 
lipophilic vitamins.  Obese patients receiving120 mg of Orlistat three times/day (a drug 
that acts as a lipase inhibitor, preventing the digestion and then, absorption of dietary 
fat) for one year had significant reduction of body mass (BM) in association with 
decrease in levels of vitamin E (VE) and β-carotene, but not vitamin A (VA) and VD 
(VD), compared with those receiving placebo, indicating the essential role of fat 
absorption in the maintenance fat-soluble vitamin homeostasis127.  Additionally, a 12-
week treatment of Orlistat (120 mg three times daily) was shown to significantly reduce 
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the plasma levels of VA and VE in addition to the reductions of body weight and fat 
mass in patients with obesity128.  Because VA shares the same routes of digestion and 
absorption as lipids, we hypothesize that VA intake will have an effect on obesity 
development in subjects consuming an obesogenic high-fat diet (HFD). 
Here, we compared the growth current and plasma parameters of rats fed a HFD 
with sufficient amount of VA (HF-VAS) and a HFD without VA (HF-VAD) diet for eight 
weeks.  
3.2 Materials and methods 
3.2.1 Animals and diets 
Male Sprague Dawley (SD) rats were bred at the University of Tennessee at 
Knoxville (a breeding colony since 2012). Our previous investigations of VA in energy 
metabolism have used Zucker fatty rats as a model for obesity6,91  Zucker fatty rats 
develop obesity because they express a missense mutation in the extracellular domain 
of all leptin receptor isoforms168.  For this investigation SD rats were used so that the 
findings can be applied to other strains of rats (protocol# 1582).  
  Animals were kept in the Animal Facility for the Nutrition Department at the 
University of Tennessee.  Facility temperatures are maintained at 70-73 ºF, the humidity 
ranges from 45-65% and has a light and dark cycle in 12 hour increments (with the lights 
on from 6:00 a.m.-6:00 p.m.)  Two to three rats were placed in a single cage and fed ad 
libitum.  Cages were cleaned twice a week and given a fresh enrichment (either a piece 
of PVC pipe or a paper cone).  They were housed in colony cages and fed either a high 
fat diet that is HF-VAD (0 IU/g VA) or HF-VAS (22.1 IU/g VA) after weaning (three weeks 
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of age) for a total of eight weeks.  This period of eight weeks will be sufficient to induce 
VA deficiency.8  The HF-VAS diet had 60% energy from fat.  Average fat intake is close 
to 30% total calories from fat, so the fat content in the experiment is double the average 
fat intake.  The HF-VAD diet was identical to the HF-VAS differing only in VA content.  
Diets for this experiment will be ordered from Harlan. 
BM and food intake (in grams) were recorded weekly6.  BM was measured for each 
rat to the nearest 0.01 gram with a calibrated scale.  Food intake was measured by 
weighing the amount of feed given at the start for the week then subtracting the amount 
remaining at the end of the week and dividing the total by the number of rats that 
consumed the diet to get each rat’s weekly intake.  All procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Tennessee at Knoxville 
(865-946-2574). 
3.2.2 Collection of plasma and tissue samples 
At the end of eight weeks of dietary treatment, plasma glucose was measured 
with an assay kit (Procedure No. 1070) from STANBIO Laboratory (Boerne, Texas).  
Rats were euthanized with CO2 and spinal cord dislocation in accordance with 
regulations.  Hepatic blood was collected and centrifuged at 3,000 rpm for 30 minutes to 
collect plasma.  Liver, white adipose, brown adipose were collected, weighed, snapped 
frozen in liquid nitrogen and stored at -80˚C. 
Before euthanization, glucose level of the tail tip whole blood was measured 
using a glucose meter (Roche; Tucson, AZ).  Tail blood (less than 10 ul) was collected 
with 25 G needle.  Once rats were euthanized, hepatic blood was collected from the 
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vena cava, then the liver and white adipose were collected.  Brown adipose was 
collected from the back of the neck.  Tissues were weighed on a calibrated scale to the 
nearest 0.01 gram, wrapped in aluminum foil and frozen with liquid nitrogen.   Plasma 
and tissue samples were then stored at -80 º C before used. 
Measuring glucose from hepatic blood was accomplished with the technique 
described Trinder et al169.  With this method, glucose is oxidized in the presence of 
glucose oxidase.  The hydrogen peroxide formed reacts, under influence of peroxidase 
with phenol and 4-aminoantipyrine to form a red-violet quinine complex.   The intensity 
of the color is proportional to glucose concentration.  Absorbance at 500 nm wavelength 
is then measured with a spectrometer from Glomax (Madison, WI).  The glucose 
reagent contains phosphate buffer (200 mmol/L), phenol (4 mmol/L), 4-Aminoantipyrine 
(0.2 mmol/L), glucose oxidase (˃15 KU/L) and peroxidase (˃1.2 KU/L). 
For glucose measurement, glucose reagent stored at 2-8 º C, was removed from 
4°C refrigerator and allowed to warm at room temperature for 30 minutes.  Plasma 
samples were removed from storage and placed on ice to thaw.  For each standard, 
sample and control, 1.0 mL reagent was added to cuvettes and warmed to 37ºC for 5 
minutes.  10μL of each sample was added to its respective cuvette, mixed gently and 
returned to 37ºC incubation.  After five minutes of incubation, absorbance of samples 

















3.2.3 Statistics  
Data was analyzed using independent-samples t test, as seen in previous 
research6,40,149.  Student t test was conducted to compare means of food intake, liver 
mass, white adipose mass, brown adipose mass, and blood glucose.  Differences were 
considered statistically significant at p < 0.05. 
For comparing BM over time, a Bonferroni correction was used to calculate the p-
value to determine if differences were considered statistically significant. BM for the 
groups was measured at baseline and then once a week for the eight week dietary 
treatment.  The Bonferroni correction was calculated as 0.05 divided by 9 (total time 
points BM was measured).  Differences in BM over time were considered statistically 
significant at p < 0.0056. 
3.3 Results  
Rate of BM gain was significantly less in rats fed HF-VAD starting at 7 weeks  
 To determine the effects of VA status on the gain of BM in SD rats, they were fed 
a HF- VAS or a HF-VAD diet for 8 weeks after weaning.  Animals were weighed once a 
week for eight weeks.  There was no significant difference in starting BM   between HF-
VAS and HF-VAD groups.  As shown in Figure 1, rats fed a HF-VAD diet grew at a 
similar rate as those fed a HF-VAS diet did for the first 6 weeks.  Starting at week 
seven, there was an observed significant difference in BM gain between the HF-VAS 
and HF-VAD groups, with the HF-VAD group weighing less.  This trend continued for 
the remainder of the diet treatment, with increasing significance.  This trend can be 
seen in Figure 1.  The BM of both groups continued to rise throughout the 8 week study 
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period.  Of note, without the Bonferroni correction, significant difference in BM was 
detected at week 6 of dietary treatment. 
Figure 2 shows the weekly food intake of the rats fed the perspective diet. Of note, the 
total food intake for both groups was not significantly different.  These results show that 
SD rats fed a HF-VAD were able to gain BM for 8 weeks.  It was not until week seven 
that the rate of BM gain began to differ significantly between HF-VAD and HF-VAS.  
This suggests that the VA storage of SD rats at weaning is sufficient to support the BM 
gain for 6 weeks without any significant reduction in the rate of BM gain.  These results 





















Figure 1 Comparison of Body Mass gain over 8 weeks of Sprague-Dawley rats 
receiving a high-fat diet and vitamin A sufficient diet (HF-VAS) and Sprague Dawley rats 
receiving a high-fat and vitamin A deficient diet (HF-VAD)(* for comparing the two 












Figure 2 Total amount of diet consumed over 8 weeks of Sprague Dawley rats fed a 
high-fat and vitamin A sufficient diet (HF-VAS) and Sprague Dawley rats fed a high-fat 























VA deficiency resulted in morphological and metabolic changes in SD rats  
The effects of VA deficiency on SD rat metabolism were analyzed after they had 
been fed a HF-VAD or a HF-VAS for 8 weeks.  As seen in Table 1, the initial BM of the 
SD rats (3 weeks after birth as weaning) fed a HF-VAD diet was similar to the HF-VAS 
groups.  After 8 weeks of diet treatment, HF-VAD group had significantly lower BM 
(267.5 ± 32.7 g vs. 386.4 ± 37.7 g).  This demonstrates the reduced somatic growth and 
VA deficiency as shown previously8. At the end of the eight weeks, liver, white adipose 
and brown adipose were collected and weighed.  There was an observed significant 
difference between the groups for liver and white adipose weight (all p<0.05), with the 
HF-VAD group having less mass for liver and white adipose.  While there was not a 
significant difference for brown adipose mass (p = 0.070).  All of these results 














Table 3 Comparison of measures for Sprague Dawley rats receiving a high-fat vitamin 
A sufficient (HF-VAS) diet and Sprague Dawley rats receiving high-fat vitamin A 
deficient (HF-VAD) diet  
Diet HF-VAD(mean±SD) (n) HF-VAS(mean±SD)(n) 
Start day BM (g) 45.5 ± 6.5 (9) 44.7 ± 3.43 (6) 
End day BM (g) 267.5 ± 32.7 (9) 386.4 ± 37.7 (6)* 
Liver mass (g) 9.01 ± 1.42 (9) 14.88 ± 1.91 (5)* 
Liver/BM ratio 1:29.7 (9) 1:25.9 (5) 
White adipose mass (g) 2.16 ± 0.91 (7) 3.8 ± 1.25 (6)* 
White adipose/BM ratio 1:123.87 (7) 1:101.68 (6) 
Brown adipose mass (g) 0.31 ± 0.099 (7) 0.45 ± 0.13 (6) 
Plasma glucose (mg/dl) 479.8 ± 179.2  (5) 434.5 ± 41.9  (4) 
Plasma cholesterol (mg/dl) 530.6 ± 12.3 (5) 537.5 ± 17.5 (4)  
Plasma triglyceride (mg/dl) 60.4 ± 30.8 (5) 70.0 ± 16.3  (4) 
 











The growth curves of SD rats fed a HF-VAD or a HF-VAS diet demonstrate that 
VA content in the diet significantly impacted obesity development (BM gain) while 
consuming an obesogenic diet.  Lack of VA in the diet began to reduce the rate of BM 
gain starting at week 7 for rats consuming the HF-VAD diet.  The rats fed a HF-VAD diet 
still gained BM at a slower rate for the remaining week of dietary treatment.  This 
difference could not be explained by any change in total energy intake because both 
HF-VAD and HF-VAS groups consumed similar total calories for the 8 week dietary 
treatment.  Our previous experiments have shown that Zucker Lean and Zucker Fatty 
rats consuming a normal chow diet deficient in VA would reach a peak BM and then 
would start to lose BM with continued dietary treatment6 in contrast to the current 
experiment where the VAD group still gained BM throughout the 8 weeks of dietary 
treatment.  A possible explanation for this difference is the high caloric content of the 
HF-VAD.  Another reason for the difference could be that VA storage in SD rats differs 
from VA storage in Zucker Lean and Zucker Fatty rats. 
The net white fat mass was significantly lower in HF-VAD subjects than HF-VAS 
subjects.  It has been demonstrated that rats fed a VAD diet had a loss of carcass fat, 
along with a reduction of BM170.  These findings indicate that VA status plays a role in 
adiposity. 
The net liver mass was significantly lower in HF-VAD subjects than HF-VAS 
subjects.  On the other hand, there was no significant difference found in liver/BM ratio 
between SD rats fed a HF-VAD diet and SD rats fed a HF-VAS diet.  A possible 
43 
 
contribution to the lower liver mass observed in the HF-VAD rats compared to the HF-
VAS rats is depleted hepatic glycogen content.  It has been observed that rats fed a VA-
deficient diet had depleted hepatic glycogen content60.  In that study it was determined 
that the depletion of hepatic glycogen was caused by the reduction of glycogenesis from 
trioses, rather than directly from glucose60.  It was shown that the depletion in VAD rats 
was not due to reduced energy intake, as pairfed rats with equal energy intake had 
higher hepatic glycogen content60.  This is comparable to the findings in the current 
study, as shown in Figure 2, SD rats fed a HF-VAD diet had equal total energy intake 
for the 8 week diet treatment as the SD rats receiving a HF-VAS diet. 
No significant difference was detected in the plasma glucose levels between the 
HF-VAD and HF-VAS groups.  Previous research from our lab showed a significant 
difference in the plasma glucose of Zucker Fatty rats fed a normal chow VAD compared 
to their VAS counterparts6.  Differences in results could possibly be attributed to the use 
of a different strain of rat.  SD rats may have greater storage of VA at weaning than 
Zucker Fatty rats and therefore may not have the same impact from a VAD diet on 
glucose metabolism. Alternatively, this difference may be caused by the presence of 
high fat content in the diets, which probably provide enough fatty acid for the muscle to 
use. This may spare glucose and prevent the drop of glucose in HF-VAD rats. 
Additionally, no significant difference was found in the plasma cholesterol and 
plasma triglycerides between the HF-VAD and HF-VAS groups.  Previous research from 
our lab showed a significant difference in the plasma triglycerides of Zucker Fatty rats 
fed a normal chow VAD compared to their VAS counterparts6.   An explanation for this 




 The current research on lipophilic vitamins in HFD has focused on their 
protective roles in HFD feeding conditions. How HFD affects homeostasis of lipophilic 
vitamins remains to be an open question. Our current findings support the assertion that 























Comparison of Dietary Vitamin A Consumption in Participants with 10% Body 


























Obesity continues to be a serious national problem with one third of the population 
considered to be obese1.  This condition increases the risk of development of various 
metabolic diseases2 such as diabetes and hyperlipidemia, resulting in higher mortality 
rates and higher costs in health care3.  Additionally, obesity has been linked to decreased 
productivity in the workplace, which can indirectly increase healthcare costs3.  The 
increases in mortality rates and costs of health care have become an urgent problem, 
which finding solutions must become priority.   
The problem of obesity is thought to be caused by positive energy balance, 
meaning that energy intake is greater than energy output4.  While over nutrition seems to 
be an obvious cause of obesity development, the role of individual micronutrients has not 
been revealed. Previous research indicates that vitamin A (VA) may play a role in the 
development of obesity6.  It has be demonstrated that patients with promyelocytic 
leukemia treated with all-trans retinoic acid (RA) experienced increases in body mass 
(BM) and plasma cholesterol105.  While this demonstrates the effects of excess VA on BM 
gain in humans, it is currently not understood how dietary VA plays a role in weight loss, 
and its role when a hypocaloric, low-fat diet is consumed. 
This project aims to investigate the effects of VA intake on BM alterations in 
participants during dietary interventions. This will be achieved by comparing dietary VA 
intake between participants who successfully lost 10% weight and those who did not at 6 
months in a lifestyle intervention.  Based on previous research, we hypothesized that 
participants who achieved 10% weight loss will have consumed significantly less dietary 
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VA than those who did not achieve 10% weight loss while consuming a hypocaloric, low-
fat diet.   
4.2 Methods 
4.2.1 Study design 
 A secondary data analysis as conducted using data collected from a previous 
published lifestyle intervention trial which examined a reduced variety dietary 
prescription165.  In the original study, 202 participants who were overweight and obese 
were randomly assigned 1 of 2 conditions:  Limited Variety (LV) or Lifestyle.  Both of the 
treatment conditions were given a standard low-calorie, low-fat diet prescription (1200 
kcal/day for participants weighing less than 200 lbs at baseline and 1500 kcal/day for 
participants weighing greater than 200 lbs at baseline, with fat being restricted to 30% of 
energy intake), a physical activity prescription consisting of 200 minutes of moderate-
intensity physical activity per week and walking 10,000 steps per day, and a cognitive 
behavioral intervention to aide in dietary and physical activity behavior changes165.  The 
LV was also given a limited variety prescription, designed to decrease the number of 
non-nutrient-dense, energy-dense foods (NND-EDF) (for example ice cream, cookies, 
chips) consumed to only 2 selected by the participants165.  The NND-EDFs also 
included modified versions such as reduced sugar and sugar free ice cream.  
Participants in the Lifestyle group did not receive the limited variety prescription. 
 Participants participated in the intervention for 18 months, which provided 48, 60 
minute group sessions.  These sessions, modeled after lessons used in the Diabetes 
Prevention Program, covered lessons on behavioral and cognitive skills to aide with 
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dietary and physical activity behavior changes.  During the first 6 months, which was 
considered the weight loss phase, participants had weekly sessions.   Months 7-18 
were considered the maintenance phase so the participants had two sessions a 
month165.  Measures were taken at baseline, 6, 12, and 18 months. 
 At the end of the study it was found that the LV group consumed less variety of 
NND-EDFs and less overall energy intake daily from these foods than the Lifestyle 
group at 6, 12, and 18 months165.  While the LV group consumed less total energy than 
the Lifestyle group at 6 months, there were no significant differences between the 
groups in energy intake at 12 and 18 months165.  Weight loss did not differ significantly 
between groups and at 18 months both groups lost approximately 9% of body weight165. 
 The current study was a secondary data analysis. The time point examined was 
month 6.  For analysis, the participants were divided into two groups, successful weight 
loss at 6 months (loss of 10% or more of body weight), and unsuccessful weight loss at 
6 months (loss of less than 10% of body weight).  Weight loss of 5-10% in overweight 
and obese subjects has been shown to improve risk factors for diseases related 
obesity171.   The dependent variables that were investigated are VA intake.  Variables 
for VA included Total Vitamin A Activity International Units, Beta Carotene provitamin A 
carotenoid, Total Vitamin A Activity Retinol Equivalents, Beta Crytoxanthin provitamin A 
Carotenoid, Alpha Carotene provitamin A carotenoid. 
4.2.2 Participants 
In the initial study, participants were recruited from Providence, RI and Knoxville, 
TN.  Eligibility criteria included aged 21-65 years, a BMI between 27 and 45 kg/m2, and 
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the ability to walk 2 blocks165.  Participants were excluded if they reported a heart 
condition, chest pain, or loss of consciousness; were taking weight loss medications or 
participating in another weight loss intervention; had undergone bariatric surgery; were 
pregnant or lactating, or less than 6 months post-partum or planning to become 
pregnant during the study; were allergic to foods being used in the taste-test measures 
conducted during the study; or were consuming less than 5 different types of NND-
EDFs165.  For the current secondary data analysis, only participants with complete 
dietary data and weight measurements at baseline and 6 months were included in the 
analyses. 
4.2.3 Measures 
Measures were collected by trained research staff blinded to the randomization 
assignment at baseline and 6 months in a research setting.  Demographic measures, 
such age and race, were collected through a self-report survey at baseline165.  Of note, 
all of the measures collected for participants were not collected at the same time of the 
year.  The study collected measures from 6 different cohorts over time. 
Anthropometrics 
Participant height was measured at baseline and weight measures were taken at 
baseline and 6 months to calculated BMI.  Height measurements were recorded to the 
nearest millimeter at baseline using a stadiometer165.  Weight was measured with a 
calibrated scaled, while wearing light street clothes, and recorded to the nearest 0.05 
kg165.  For this study, percentage weight loss was used to assess weight loss.   
Percentage weight loss was calculated as: 
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𝑊𝑒𝑖𝑔ℎ𝑡 𝑙𝑜𝑠𝑠 % =  





Looking at participant dietary intake, three random 24-hour dietary recalls were 
collected by phone during a 1 week period at 0 and 6 months.  Recalls were conducted 
by interviewers from the Cincinnati Center for Nutritional Research and Analysis trained 
and blinded to the intervention and interventions assignment165. 
The Nutrition Data System Software for Research developed by the Nutrition 
Coordinating Center, University of Minnesota, Minneapolis, MN was used to collect and 
analyze the 3-day food records.  The multiple-pass method was used to collect the data.  
There are 5 phases for this method of recall of dietary data.  In the first phase, the 
participant tells the reviewer all of foods and beverages that were consumed.  The 
second phase occurs when the reviewer reviews the list with the participant.  In the third 
phase, the interviewer receives detailed information of the foods and beverages 
consumed.  In the fourth phase, participants were given 2-dimensional models of food 
portions sizes to assist with accurate reporting.  In the fifth phase the reviewer reviews 
the entered information with the participants to ensure completeness. 
Variables for dietary intake were calculated as means of the three days.  
Variables include VA as Total Vitamin A Activity International Units, Beta Carotene 
provitamin A carotenoid, Total Vitamin A Activity Retinol Equivalents, Beta Crytoxanthin 




 Independent t-tests and chi-squared tests were conducted to compare 
demographics and anthropometrics measures between participants included in the 
secondary data analyses and those not included.  A significant difference was found 
between those included and those not included in the analyses for education, which 
was entered as a covariate in the remaining analyses. 
For participants included in this secondary analysis, independent t-tests and chi-
squared tests were used to compare demographics and baseline anthropometrics, and 
baseline dietary intake of selected VA variables between those who had successful 
weight loss at 6 months and those who did not have successful weight loss at 6 months.  
No significant differences were found between the two groups for baseline measures.   
To determine if there was a significant difference in the amount of dietary VA 
consumed at 6 months between participants with successful weight loss and 
participants who did not have successful weight loss, a mixed analysis of covariance 
(ANCOVA) was conducted, with weight loss % (10% weight loss at 6 months and less 
than 10% weight loss at 6 months) as the between-subjects variable and time (6 
months) as the within-subjects variable, and education as a covariate. 







Baseline participant characteristics 
Baseline characteristics for those included in the analyses (n= 113) compared to 
those that were excluded from the analyses (n=89) are shown below in Table 4.  No 
significant difference was found in weight, BMI, gender, race, ethnicity, marital status, 
age, and group assignment.  A significant difference was found between these groups 
for education, with those included in the analyses having a higher percentage of having 
some college education or higher than those not included in the analyses (91.2 % vs. 
83.1 %).  Therefore, education was entered as a covariate in all subsequent analyses. 
Baseline characteristics for the successful weight loss and unsuccessful weight 
loss groups are shown in Table 5 below.  Participants were 51.9 ± 8.8 years, 
predominately white (94.7%), female (59.6%), with some college education (91.2%), 
married (75.2%) and not Hispanic (100%), and were obese (BMI = 35.0 ± 4.5). No 
significant differences were detected for baseline characteristics and self-reported 
dietary intake of VA between the groups.  
Comparison of self-reported dietary intake of VA at 6 months between groups 
 There was no significant difference found for self-reported dietary intake of any of 
the VA variables at 6 months between participants with successful weight loss and 
participants with unsuccessful weight loss.  See Table 6 below for comparison of means 




Table 4 Baseline characteristics for participants included vs. those not included in 
secondary analyses 
Variable Not Included (n=89) Included (n=113) 
Age (y) 51.9 ± 8.8 51.9 ± 8.8 
Weight (lb) 218.9 ± 38.1 223.3 ± 40.2 
BMI (kg/m2) 34.4 ± 3.9 35.0 ± 4.5 
Female (%) 55.1 59.3 
White (%) 88.8 94.7 
Non-Hispanic (%) 98.9 100 
Some college education or higher (%)* 83.1 91.2 
Married (%) 71.9 75.2 
Lifestyle assignment (%) 48.3 52.2 
 











Table 5 Baseline characteristics and self-reported dietary intake of vitamin A for 
participants with successful weight loss and participants with unsuccessful weight loss 
(M± SD) 
Variable Successful 
weight loss (n = 
66) 
Unsuccessful 
weight loss (n 
= 47) 
Age (y) 53.3 ±8.3 50.0 ±9.2 
Weight (lb) 220.6 ± 40.6 227 ± 39.8 
BMI (kg/m2) 34.7 ± 4.6 35.5 ± 4.4 
Female (%) 59.1 59.6 
White (%) 93.9 95.7 
Non-Hispanic (%) 100 100 
Some college education or higher (%)* 92.4 89.4 
Married (%) 70.0 83.0 
Lifestyle assignment (%) 48.5 57.4 
Beta Carotene provitamin   A carotenoid         
(mcg) 
3724.0 ± 2984.2 2815.6 ± 
2632.9 
Total Vitamin A Activity  Retinol Equivalents 
(mcg) 
1304.6 ± 770.9 1006.9 ± 
528.8 
Total Vitamin A Activity  Retinol Activity 
Equivalents (mcg) 
959.0 ± 571.2 748.5 ± 
362.4  
Beta Crytoxanthin  provitamin A carotenoid 
(mcg) 
149.0 ± 175.5 97.8 ± 
110.8 
Alpha Carotene provitamin  A carotenoid 
(mcg) 
692.7 ± 737.7 472.8 ± 
511.5 
Total Vitamin A Activity  International Units 
(IU) 
8956.2 ± 5897.4 6802.5 ± 
4692.8 
 





Table 6 Comparison of means of dietary vitamin A between participants with successful 
10% weight loss and participants with less than 10% weight loss (M± SD) 
Variable Successful weight 
loss (n = 66) 
Unsuccessful 
weight loss (n 
= 47) 
Beta Carotene provitamin A carotenoid 
(mcg) 
3625.54± 3094.07 3109.14± 
3171.55 
Total Vitamin A Activity Retinol Equivalents 
(mcg) 
1022.07± 579.31 989.20± 590.79 
Total Vitamin A Activity Retinol Activity 
Equivalents (mcg) 
688.91± 341.65 701.83± 364.68 
Beta Crytoxanthin provitamin A carotenoid 
(mcg) 
124.28± 125.26 122.48± 119.17 
Alpha Carotene provitamin A carotenoid 
(mcg) 
619.82± 595.45 555.37± 556.15 
Total Vitamin A Activity International Units 
(IU) 
7848.80± 5501.16 7129.18± 
5542.82 
 









4.4 Discussion  
           The purpose of this investigation was to examine the relationship between 
dietary VA and weight loss in participants in a lifestyle intervention.  This was 
accomplished by comparing the amount of VA consumed between participants who 
successfully lost 10% weight and those who did not while consuming a hypocaloric, low-
fat diet.  Since no significant difference was detected in amount of VA consumed 
between the groups, the results indicate that the amount of VA consumed in a weight 
loss intervention where participants are experiencing a negative energy balance and 
restricting fat did not have a relationship with weight loss.     
          There is limited human research investigating the effect of VA on obesity and the 
previous research on the relationship between VA intake and obesity in humans has 
mostly focused on the effects of excessive VA intake, and VA influence on weight gain, 
rather than loss105,117-118.  There is a need for further investigation on how VA intake 
impacts weight loss. 
           In contrast to the first experiment for this thesis project, this experiment used a 
human model where the goal for the participants was weight loss rather than weight 
gain, as seen in the animal experiment.  The diets also differed in that the participants 
were instructed to follow a hypocaloric, low-fat diet as opposed to the obesogenic, high-
fat diet provided to the animal subjects.  Dietary fat is essential for absorption of VA, 
and restriction of fat may have played a role in the results of this experiment.  Even if 
participants consumed VA rich foods, if they did not also consume adequate fat, then 
the VA would not have been absorbed to exert its physiological effects.   
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           One limitation of this study would be that the sample was homogenous in race 
and ethnicity.  Another limitation would be the use of self-reported dietary data.  The 
sample of those included in the analysis was also greatly reduced due to participants 
being excluded from the analysis from lack of complete dietary data.  Also, it is 
important to note the large variation of average VA intake (based on a large standard 
deviation) for participants in both groups.  Additionally, since the study design was a 
secondary data analysis conclusions on cause and effect cannot be made. 
4.5 Conclusion 
         Our findings indicate that VA intake does not play a role in weight loss.  Since the 
weight loss intervention called for a restriction on fat intake, absorption of VA may have 
been impacted.  If VA absorption was impaired, it would not be able to carry out its 
physiological activities.   
         It is important to note the contrast between the experiments used for this thesis 
project.  The first experiment used an animal model to examine the relationship 
between VA intake and weight gain (obesity development) in HFD feeding conditions, 
while the second experiment used a human model to look at the relationship between 
VA intake and weight loss with a diet that was hypocaloric and low-fat.   Even if the 
results of the animal experiment indicate that VA plays a role in weight gain while 
consuming an obesogenic HFD, this does not mean that VA plays a role in weight loss 
when consuming a diet that is hypocaloric and low-fat.  It is possible that fat content in 
the diets for these experiments played a role in the results we have seen.  The 
relationship between VA intake and weight management may depend on the fat content 
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of the diet.  Another explanation for the results could be the negative energy balance 
state used in this experiment.  It is possible that VA does not influence weight 




Chapter V  



















This thesis project incorporated two different models to investigate the impact of 
VA in obesity.  The first was an animal model, where animals were fed a high-fat diet 
with the goal of weight gain during dietary treatment.  The second model looked at 
humans, where participants’ fat and energy intake were restricted with the goal of 
achieving weight loss during the intervention.  Because one model investigates weight 
gain and the other investigates weight loss, two different models (weight loss and 
weight gain), and two different diets (high-fat and low-fat) were examined.   
We have known that vitamin A (VA) status affects plasma lipids levels, which is 
supported by the results of the animal experiment.  The current research on lipophilic 
vitamin in high-fat diet (HFD) has focused mostly on the protective roles of lipophilic 
vitamins in HFD feeding conditions.  How HFD affects homeostasis of lipophilic vitamins 
remains to be an open question.  Knowing the essentiality of lipophilic vitamins for 
general healthy, it can be easy to assume that their uptake is helpful in a variety of 
dietary conditions.  However, their uptakes share the same route as dietary lipids.  
Mutual effects of dietary lipophilic vitamins and other lipid molecules on each other’s 
digestions, absorption and functions may exists.  Our current findings support the 
assertion that VA status plays a key role in adiposity in HFD conditions.  It is feasible to 
assume that transport, storage and metabolism of these lipophilic vitamins alter with the 
change of diets or metabolic states of a subject or population.  Additional studies are 
needed to understand the impacts of dietary components on the homeostasis of 
lipophilic vitamins. Additional biochemical studies are need to analyze all the samples 
collected. The expression levels of glucose and lipid metabolic enzymes in the 
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metabolic active tissues and organs, such as the liver, adipose tissue and muscle will 
certainly reveal the metabolic changes introduced by the elimination of VA in a diet of 
high-fat setting. 
Since our current findings showed no significant difference of VA intake between 
participants who had successfully lost 10% weight and those who had not, this indicates 
that intake of lipophilic vitamins was not related to weight loss.  It has been established 
that excessive VA intake can contribute to BM gain in participants without changes in 
caloric intake, but it is not known if VA intake plays a role in weight loss when a 
hypocaloric, low-fat diet is consumed.  While the results of the animal experiment 
indicate that VA plays a key role in weight gain in HFD conditions, the relationship (if 
any) between VA intake, fat intake, and weight loss remains to be an open question.  
Additional studies are needed to understand the role VA plays in the process of weight 
loss.  The amount of fat consumed could have affected the results of the current 
experiment.  Dietary fat is required for VA absorption.   It is possible that the effects of 
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